| Cardiorenal end points in a trial of aliskiren for type 2 diabetes HH Parving, BM Brenner, JJV McMurray, D De Zeeuw, SM Haffner, ... New England Journal of Medicine 367 (23), 2204-2213, 2012 | 1624 | 2012 |
| Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ... The Lancet 392 (10157), 1519-1529, 2018 | 1329 | 2018 |
| NEW-ONSET DIABETES AFTER TRANSPLANTATION: 2003 INTERNATIONAL CONSENSUS GUIDELINES1 J Davidson, A Wilkinson, J Dantal, F Dotta, H Haller, D HERNandez, ... Transplantation 75 (10), SS3-SS24, 2003 | 1010* | 2003 |
| Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that β-cell death is caspase mediated, partially dependent … R Lupi, F Dotta, L Marselli, S Del Guerra, M Masini, C Santangelo, ... Diabetes 51 (5), 1437-1442, 2002 | 852 | 2002 |
| Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial RE Pratley, M Nauck, T Bailey, E Montanya, R Cuddihy, S Filetti, ... The Lancet 375 (9724), 1447-1456, 2010 | 758 | 2010 |
| Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients KT Coppieters, F Dotta, N Amirian, PD Campbell, TWH Kay, MA Atkinson, ... Journal of Experimental Medicine 209 (1), 51-60, 2012 | 721 | 2012 |
| Coxsackie B4 virus infection of β cells and natural killer cell insulitis in recent-onset type 1 diabetic patients F Dotta, S Censini, AGS van Halteren, L Marselli, M Masini, S Dionisi, ... Proceedings of the National Academy of Sciences 104 (12), 5115-5120, 2007 | 717 | 2007 |
| Latent autoimmune diabetes in adults (LADA) should be less latent S Fourlanos, F Dotta, CJ Greenbaum, JP Palmer, O Rolandsson, ... Diabetologia 48, 2206-2212, 2005 | 499 | 2005 |
| Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial AJ Ahmann, M Capehorn, G Charpentier, F Dotta, E Henkel, I Lingvay, ... Diabetes care 41 (2), 258-266, 2018 | 452 | 2018 |
| Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse F Calcinaro, S Dionisi, M Marinaro, P Candeloro, V Bonato, S Marzotti, ... Diabetologia 48, 1565-1575, 2005 | 451 | 2005 |
| Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with Type 2 diabetes (DURATION-4) a 26 … D Russell-Jones, RM Cuddihy, M Hanefeld, A Kumar, JG González, ... Diabetes care 35 (2), 252-258, 2012 | 402 | 2012 |
| Guidelines for the treatment and management of new‐onset diabetes after transplantation1 A Wilkinson, J Davidson, F Dotta, PD Home, P Keown, B Kiberd, ... Clinical transplantation 19 (3), 291-298, 2005 | 357 | 2005 |
| Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial HW Rodbard, J Rosenstock, LH Canani, C Deerochanawong, ... Diabetes care 42 (12), 2272-2281, 2019 | 332 | 2019 |
| Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised … P Dandona, C Mathieu, M Phillip, L Hansen, SC Griffen, D Tschöpe, ... The lancet Diabetes & endocrinology 5 (11), 864-876, 2017 | 302 | 2017 |
| Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes L Gennari, D Merlotti, R Valenti, E Ceccarelli, M Ruvio, MG Pietrini, ... The Journal of Clinical Endocrinology 97 (5), 1737-1744, 2012 | 301 | 2012 |
| High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes R Buzzetti, S Di Pietro, A Giaccari, A Petrone, M Locatelli, C Suraci, ... Diabetes care 30 (4), 932-938, 2007 | 288 | 2007 |
| Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. MG Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E ... Diabetes Obes Metab. 16 (10), 1016-1027, 2014 | 284 | 2014 |
| CD4+ CD25high regulatory T cells in human autoimmune diabetes AL Putnam, F Vendrame, F Dotta, PA Gottlieb Journal of autoimmunity 24 (1), 55-62, 2005 | 277 | 2005 |
| Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin … O Vaccaro, M Masulli, A Nicolucci, E Bonora, S Del Prato, AP Maggioni, ... The lancet Diabetes & endocrinology 5 (11), 887-897, 2017 | 273 | 2017 |
| A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets P Marchetti, R Lupi, M Bugliani, CL Kirkpatrick, G Sebastiani, FA Grieco, ... Diabetologia 55, 3262-3272, 2012 | 270 | 2012 |
